BISBUDIAME, AN ESTROGEN DERIVATIVE WITH AN ANTITHROMBOTIC EFFECT

Abstract number: P-S-662

de la Peña¹ A., Gonzalez-Alva² C., Fernandez-G³ J., Pinzon⁴ E., Torres⁵ I., Bahena² A., Mendoza⁶ G.

¹¹Farmacologia - Facultad de Medicina, Universidad Nacional Autonoma de Mexico ²²Farmacologia, Instituto Nacional de Cardiologia ³³Quimica Inorganica- Instituto de Quimica ⁴⁴Bioterio - Facultad de Medicina ⁵⁵Bioterio- Facultad de Medicina, Universidad Nacional Autonoma de Mexico ⁶⁶Laboratorio de Urgencias, Instituto Nacional de Cardiologia, Mexico City, Mexico

How-to-cite de la Peña A, Gonzalez-Alva C, Fernandez-G J, Pinzon E, Torres I, Bahena A, Mendoza G. BISBUDIAME, AN ESTROGEN DERIVATIVE WITH AN ANTITHROMBOTIC EFFECT. J Thromb Haemost 2007; 5 Supplement 2: P-S-662

Abstract

Introduction: Women taking exogenous estrogens have shown an increased risk of venous and arterial thrombosis compared with non-users. We had designed and synthesized Bisbudiame, a new di-amino-estrogen derivative obtained by the reaction of estrone with aminobutanol followed by reduction with sodium borohydride. We determined the anticoagulating effect of the synthetic estrogen and compared the weight of the surgically-induced thrombus in the artery and femoral vein of pre-treated mice with Bisbudiame or with dimetylsulfoxide (DMSO) as a control group.

Methods: The estrogen derivative was synthesized at Instituto de Química, UNAM. A dose-response curve was performed employing CD1 male mice to determine the anticoagulant effective dose 50 (ED50). The compound, dissolved in DMSO, was administered by an intraperitoneally injection. After 24 h, the modified tail bleeding time assay was employed to evaluate hemostasis. Also, prothrombine time and activated thromboplastine time (ATTP) were performed employing 0.11 M sodium citrate as anticoagulant. After 24 h of pre-treatment (1.2 mg/100g body weight), anesthetized mice underwent surgically-induced thrombosis by tightening two sutures separated by 0.7 cm for 2 h, to complete obstruct the blood flow in the right leg femoral vasculature. The thrombus were removed, rinsed, dried overnight, and weighted

Results: Anticoagulant ED50 was 1.2 mg/100g body weight. The bleeding time was two-fold increased* (t-test), ATTP was 1.6 fold increased, whereas the thrombus weight was 2.5-fold decreased in the Bisbudiame-treated group, in comparison to the control group

Conclusions: Results showed that Bisbudiame 1.2mg/100g body weight in mice has an antithrombotic effect

To cite this abstract use the following format:

Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number

Session Details

Date:	01/08/2007
Time:	00:00-00:00
Session name:	XXIst ISTH Congress
Subject:
Location:	Oxford, UK
Presentation type:
Back to top